14 March 2023 | News
To further support the strategic development and positioning of the company
Leading contract manufacturer and service provider for plasmid and minicircle DNA - PlasmidFactory - has announced the appointment of two board members, Berthold Hackl and Dr Eduard Ayuso as chairman and member of the board, respectively.
The two industry experts are joining Germany-based PlasmidFactory’s board to further support the strategic development and positioning of the company; their vast industrial and scientific insight will contribute significantly to PlasmidFactory’s growth acceleration.
PlasmidFactory opened a new HQ (High Quality) production facility that is generating high quality, cutting-edge plasmids as well as minicircles in large scale, and since partnering with global healthcare-focused private equity firm ARCHIMED in September 2022, has been working actively to build a GMP (Good Manufacturing Practices)-compliant facility to continue meeting the needs of the client base.
This carefully planned capacity expansion will allow PlasmidFactory to further establish and leverage its unrivaled reputation as provider of exceptionally high quality and reliable starting materials for gene and cell therapy as well as RNA vaccines.
Both industry experts were recruited through ARCHIMED’s MedTalents, a global network of associated senior healthcare executives who identify, facilitate and advise on deals and counsel portfolio companies.
Berthold Hackl is a successful executive, advisor and board member in the life sciences across VC, PE and public environments and at various life sciences related companies. He brings with him over thirty years of industrial experience in Europe and the US in the areas of equity raising, buy-and-build, exits and the development of new markets.
Berthold Hackl has extensive supervisory board experience in biopharma, medtech and diagnostics companies. As General Manager Europe for Eurofins he grew the company’s biopharma and medtech platforms through M&A and organic growth initiatives. Hackl previously worked for a number of companies in biopharma and medtech, including a role as CEO of invendo medical (now AMBU), strategic players Synthes (now J&J) and Biacore (now Danaher).
Dr Eduard Ayuso brings to PlasmidFactory an extensive experience in the use of plasmids as starting materials for manufacturing ATMPs, molecular knowledge on the design of AAV helper plasmids and an international network of industry and academic experts in the field of gene therapies. He is currently the Chief Technology Officer at DiNAQOR (Zürich, Switzerland), a genetic medicine platform company focused on addressing severe inherited cardiac and kidney diseases and CEO of DINAMIQS (Zurich, Switzerland) a CDMO providing a comprehensive range of manufacturing services, process development, quality control and analytics solutions to support and optimize the most promising gene therapy projects.